It looks to be difficult even with the experts. That is why I give my "advice" in spite nobody asks.
Generic manufacturers will benefit most, they get new "patent-protected" drugs with PBT2 added to the different generic molecules. The antibiotic-resistant fund should support those who will do the studies to get these "new" molecules to the market and get repaid when the drugs get to the market. Every company starting to develop and market needs to do a deal with ATH, with up-front money and royalties.
As you can see, there is nothing new in this proposal, it is somehow told in the fund's presentation.
With the still under patent protection antibiotics, the companies need to do their individual deals with ATH. The fund money is not needed for these.
It looks to be difficult even with the experts. That is why I...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $20.98M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $14.55K | 3.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 71906262 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 32338803 | 25 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |